-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target

Benzinga·08/19/2026 10:25:59
語音播報
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.